Immunotherapeutic Agents for Intratumoral Immunotherapy
Vaccines · 14.11.2023 · 11 (11) · 1717
DOI: 10.3390/vaccines11111717 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 14.11.2023. Verfasst von Chih-Rong Shyr und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404328, Taiwan. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, China Medical University Hospital, China Medical University Hospital (CMUH), Taiwan.
Abstract (Originalsprache)
Immunotherapy using systemic immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cells has revolutionized cancer treatment, but it only benefits a subset of patients. Systemic immunotherapies cause severe autoimmune toxicities and cytokine storms. Immune-related adverse events (irAEs) plus the immunosuppressive tumor microenvironment (TME) have been linked to the inefficacy of systemic immunotherapy. Intratumoral immunotherapy that increases immunotherapeutic agent bioavailability inside tumors could enhance the efficacy of immunotherapies and reduce systemic toxicities. In preclinical and clinical studies, intratumoral administration of immunostimulatory agents from small molecules to xenogeneic cells has demonstrated antitumor effects not only on the injected tumors but also against noninjected lesions. Herein, we review and discuss the results of these approaches in preclinical models and clinical trials to build the landscape of intratumoral immunotherapeutic agents and we describe how they stimulate the body’s immune system to trigger antitumor immunity as well as the challenges in clinical practice. Systemic and intratumoral combination immunotherapy would make the best use of the body’s immune system to treat cancers. Combining precision medicine and immunotherapy in cancer treatment would treat both the mutated targets in tumors and the weakened body’s immune system simultaneously, exerting maximum effects of the medical intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404328, Taiwan.
- eXCELL Biotherapeutics Inc., Taichung 404328, Taiwan.
- Department of Medicine, Department of Surgery, College of Medicine, China Medical University and Hospital, Taichung 404328, Taiwan.
- Department of Medicine, Urology Division, China Medical University and Hospital, Taichung 404328, Taiwan.
Förderung
- National Science and Technology Council, Taiwan
- China Medical University Hospital
- China Medical University Hospital (CMUH), Taiwan
Zitieren
APA
Shyr, C. R., Liu, L. C., Chien, H. S., & Huang, C. P. (2023). Immunotherapeutic Agents for Intratumoral Immunotherapy. Vaccines, 11(11), 1717. https://doi.org/10.3390/vaccines11111717
Vancouver
Shyr CR, Liu LC, Chien HS, Huang CP. Immunotherapeutic Agents for Intratumoral Immunotherapy. Vaccines. 2023;11(11):1717. doi:10.3390/vaccines11111717
BibTeX
@article{Shyr2023,
author = {Shyr, Chih-Rong and Liu, Lang-Chi and Chien, Hui-Shan and Huang, Chi-Ping},
title = {Immunotherapeutic Agents for Intratumoral Immunotherapy},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {11},
pages = {1717},
doi = {10.3390/vaccines11111717}
}
EUVIMED